Mutations in the HTT gene, which cause Huntington’s disease, lead to abnormalities in development as early as two weeks after…
Articles by Marisa Wexler, MS
Sage Therapeutics is recruiting participants for a clinical trial to test the effects of its experimental therapy SAGE-718 on…
People with Huntington’s disease who have a greater sense of purpose and meaning are more likely to find contentment…
Certain people with Huntington’s disease — specifically, younger adults with milder disease — may have benefited from treatment with…
People with Huntington’s disease are more likely to take Austedo (deutetrabenazine) as directed, compared with the similar medication…
The experimental oral medication branaplam (LMI070) has been granted fast track designation by the U.S. Food and Drug Administration (FDA)…
AMT-130, an investigational gene therapy for the treatment of Huntington’s disease, was overall well-tolerated up to a year…
Treatment with valbenazine significantly lessened chorea — a motor symptom characterized by jerky, unpredictable, and involuntary movements — in…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to SAGE-718 as a potential therapy for…
Huntington’s disease patients who have not yet developed symptoms have a different relationship with time than otherwise-healthy individuals, according…